% | $
Quotes you view appear here for quick access.

Johnson & Johnson Message Board

  • techglass1 techglass1 Mar 12, 2013 10:53 PM Flag

    JNJ at 78,56 is selling at 14.5x 2013 year end numbers that is fully valued

    They are going to earn $5.41 this year on a 4% revenue growth rate and 5.74 next year . Since companies sell base on the amount of growth they have lets be generous and give JNJ a 12 multiple or 2x its growth. Based on that the stock would be selling at $64.90 a share. It is way too high to be selling at almost15x earnings with little to no growth.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think $86-90 is a decent 1 year target based on 15x next years estimates. JNJ has a dividend yield nearly 2x that of US Treasuries + a much better balance sheet than the US Gov't. The Emerging Markets will be next lever of growth for Consumer Staples and Rx Drugs -- the Middle Class of India, China, Brazil and Africa are all emerging over the next decade, and want what JNJ and the others sell... the secular growth story is still intact and will continue for years to come.

      I remember in the Mid-90's the last time Consumer Stocks were considered growth names -- and PG bought Gillette for 30x P/E... and most names were trading in the 25X p/e area.

      I think if JNJ (and many blue chip S&P 500) became more confident -- they would start buying back more stock and boosting dividends. JNJ is extremely underleveraged --- Net Debt Free...crazy !!

      Sentiment: Buy

    • Long term EPS growth rate 7% and five year trailing growth rate 9% according to Edward Jones.

    • did you sell?

113.44-1.43(-1.24%)Oct 21 4:01 PMEDT